University of Pittsburgh PITT HOME  |  FIND PEOPLE  |  CONTACT US
  Pittsburgh Molecular Libraries Screening Center
vogt.jpg Andreas Vogt
Research Assistant Professor
10047 BST3
3501 5th Ave
Pittsburgh, PA 15260
Phone: (412) 623-1216
Fax: (412) 623-1212
  • BS (Pharmacy) University of Hamburg, Germany, 1985.
  • PhD (Pharmaceutical Chemistry) University of Hamburg, 1990.
    1. Vogt, A., McDonald, P.M., Tamewitz, A., Sikorski, R.P., Wipf, P., John J. Skoko, III, and Lazo, J.S. (2008) A cell-active inhibitor of mitogen activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Molecular Cancer Therapeutics 7 (3), 330-340 (2008)
    2. Raccor, B.S., Vogt, A., Sikorski, R.P., Balachandran, R., Montgomery, K., Shin, Y., Fukui, Y., Jung, W.-H., Curran, D.P. and Day, B.W. (2008) Cell-based and biochemical structure-activity analyses of analogues of the microtubule stabilizer dictyostatin. Molecular Pharmacology 73 (3), 718-726 (2008)
    3. Vogt, A., and Lazo, J.S. Implementation of high-content assay for inhibitors of mitogen-activated protein kinase phosphatases. Methods 42, 268-277 (2007)
    4. Wang, Z., McPherson, P.A., Day, B.W., *Vogt, A., Raccor, B., and Wipf. P., Structure-Activity and High-Content Imaging Analyses of Novel Tubulysins. Chemical Biology and Drug Design 70 (2), 75-86 (2007)
    5. Jung, W.-H., Harrison, C., Shin, Y., Fournier, J.-H., Balachandran, R., Raccor, B.S., Sikorski, R.P., Vogt, A., Curran, D.P. and Day, B.W. Total synthesis and biological evaluation of C16 analogs of (–)-dictyostatin J. Med. Chem. 50 (13), 2951-2966 (2007)
    6. Shin, Y., Fournier, J.-H., Brückner, A.M., Madiraju, C., Balachandran, R., Raccor, B.S., Edler, M.D., Hamel, E., Sikorski, R.P., Vogt, A., Day, B.W. and Curran, D.P. Synthesis and biological evaluation of (–)-dictyostatin and stereoisomers. Tetrahedron 63, 8537-8562 (2007)
    7. *Vogt, A., and Lazo, J.S., Discovery of Protein Kinase Phosphatase Inhibitors, in: High Content Screening – A Powerful Approach to Systems Cell Biology and Drug Discovery, Methods in Molecular Biology 356, 389-400 (2006)
    8. Lazo, J.S., Nunes, R., Skoko, J.J., Pierre E. Queiroz de Oliveira, P.E., Vogt, A., and Wipf, P., Novel Benzofuran Inhibitors of Human Mitogen-activated Protein Kinase Phosphatase-1. Bioorganic and Medicinal Chemistry 14, (16), 5643-5650 (2006)
    9. Wipf, P., Graham, T.H., Vogt, A., Sikorski, R.P., Ducruet, A.P., and Lazo, J.S. (2006) Cellular analysis of Disorazole C1 and structure-activity relationship of analogs of the natural product. Chemical Biology & Drug Design 67, 66-73
    10. Ohkanda,J., Strickland,C.L., Blaskovich,M.A., Carrico,D., Lockman,J.W., Vogt,A., Bucher,C.J., Sun,J., Qian,Y., Knowles,D., Pusateri,E.E., Sebti,S.M., and Hamilton,A.D. (2006). Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. Org. Biomol. Chem. 4, 482-492.
    11. *Vogt, A., Tamewitz, A., Skoko, J., Sikorski, R.P., Giuliano, K.A., and Lazo, J.S. The benzo[c ]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. Journal of Biological Chemistry 280, (19), 19078-09086 (2005)
    12. Vogt, A., and Lazo, J.S., Chemical Complementation: A Definitive Phenotypic Strategy for Identifying Small Molecule Inhibitors of Elusive Cellular Targets. Pharmacology & Therapeutics 107, 212-221 (2005)
    13. Ducruet, A. P.; Vogt, A., Wipf, P.; Lazo, J. S. Dual Specificity Protein Phosphatases: Therapeutic Targets for Cancer and Alzheimer’s Disease. Ann. Rev. Pharm. Toxicol. 45, 725-750 (2005)
    14. Vogt, A., Kalb, E.N. , and Lazo, J.S. A scalable high-content cytotoxicity assay insensitive to changes in mitochondrial metabolic activity. Oncology Research 14, 305-314 (2004)
    15. Brisson M., Nguyen, T., Vogt, A., Yalowich, J., Giorgianni, A., Tobi, D., Bahar, I., Stephenson, C.R.J., Wipf, P., and Lazo, J.S. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Molecular Pharmacology, 66 (4), 824-833 (2004)
    16. Nemoto, K., Vogt, A., and Lazo, J.S. Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells The Prostate 58, (1), 95-102 (2004)
    17. Vogt, A., Cooley, K.A., Brisson, M., Tarpley, M.G., Wipf, P., and Lazo, J.S. Identification of DSPase inhibitors by high content screening in intact mammalian cells. Chemistry & Biology 10, 733-742 (2003)
    18. *Vogt, A., Pestell, K.E., Day, B.W., Lazo, J.S., and Wipf, P. The antisignaling agent SC-9 is a structurally unique phospholipid analog with Phospholipase C inhibitory activity. Molecular Cancer Therapeutics 1, 885-892 (2002)
    19. Vogt, A.,Adachi,T.,Ducruet,A.P.,Chesebrough, J.,Nemoto, K., Carr, B.I., and Lazo, J.S., Spatial analysis of key signaling proteins by high-content solid-phase cytometry in Hep3B cells treated with an inhibitor of Cdc25 dual-specificity phosphatases. Journal of Biological Chemistry 276, (23), 20544-20550 (2001)
    20. Lazo, J.S., Aslan, D.C., Southwick, E.S., Cooley, K., Ducruet, A.P., Joo, B., Vogt, A., and Wipf, P. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. Journal of Medicinal Chemistry, 44, (24), 4042 – 4049 (2001)
    21. Lazo, J.S., Tamura, K., Vogt, A., Jung, J.-K., Rodriguez, S., Day, B.W., and Wipf, P. Antimitotic actions of a novel analog of the fungal metabolite palmarumycin CP1 Journal of Pharmacology and Experimental Therapeutics 296, (2), 364-371 (2001)
    22. Vogt A., Tamura, K, and Lazo, J.S. Antitumor disulfide IV-2 causes irreversible G2/M cell cycle arrest without hyperphosphorylation of the cyclin-dependent kinase Cdk1. Journal of Pharmacology and Experimental Therapeutics 294 (3), 1070–1075 ( 2000)
    23. Vogt, A., Wang, A., Fabisiak, J.F., Johnson, C.S., Wipf, P. and Lazo J.S. In vivo antitumor activity and induction of insulin-like growth factor –1 resistant apoptosis by SC-9. Journal of Pharmacology and Experimental Therapeutics 292 (2), 530-537 (2000)
    24. Vasudevan, A., Qian, Y., Vogt, A., Blaskovich, M.A., Ohkanda, J., Sebti, S.M., and Hamilton, A.D. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. Journal of Medicinal Chemistry 42 (8), 1333-1340 (1999)
    25. Qian Y., Marugan J.J., Fossum R.D., Vogt A., Sebti S.M., and Hamilton A.D. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors. Bioorganic and Medicinal Chemistry 7(12), 3011-3024 (1999)
    26. Vogt, A., Rice, R.L., Settinieri, C., Yokokawa, F., Yokokawa, S., Wipf, P., and Lazo, J.S. Disruption of IGF-1 signaling and downregulation of Cdc2 by SC-9, a novel small molecule antisignaling agent identified in a targeted array library. Journal of Pharmacology and Experimental Therapeutics 287(2),806-813 (1998)
    27. Qian, Y., Vogt, A., Vasudevan, A., Sebti, S.M., and Hamilton, A.D., Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics. Bioorganic and Medicinal Chemistry 6 (3), 293-299 (1998)
    28. Vogt, A., Sun, J., Qian,Y., Hamilton, A.D., and Sebti, S.M., The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21WAF/CIP/SDI in a p53 independent manner. Journal of Biological Chemistry 272, 27224-27229 (1997)
    29. Vogt, A., Qian,Y., McGuire, T.F., Hamilton, A.D., and Sebti, S.M., Protein geranylgeranylation, not farnesylation, is required for the G1¬ to S phase transition in mouse fibroblasts.Oncogene13,1991-1999(1996)
    30. McGuire, T.F., Qian,Y., Vogt, A., Hamilton, A.D., and Sebti, S.M., Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. Journal of Biological Chemistry 271, 27402-27407 (1996)
    31. Qian, Y., Vogt, A., Sebti, S.M., and Hamilton, A.D., Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors. Journal of Medicinal Chemistry 39, 217-223 (1996).
    32. Vogt, A., Sun, J., Qian, Y., Tan-Chiu, E., Hamilton, A.D. and Sebti, S.M., Burkitt lymphoma Daudi cells contain two distinct farnesyltransferases with different divalent cation requirements. Biochemistry 34, 12398-12403 (1995)
    33. Lerner, E.C., Qian, Y., Blaskovich, M.A., Fossum, R.D., Vogt, A., Sun, J., Cox, A.D., Der, C.J., Hamilton, A.D. and Sebti, S.M., Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras/Raf complexes. Journal of Biological Chemistry 270, 26802-26806 (1995)
    34. Kauffmann, R.C., Qian, Y., Vogt,A.,Sebti,S.M.,Hamilton,A.D.and Carthew,R.W. Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors.Proc.Natl.Acad.Sci.USA 92,10919-10923(1995)
    35. Vogt, A., Qian, Y., Blaskovich, M.A., Fossum, R.D., Hamilton, A.D., and Sebti, S.M., A non-peptide mimetic of Ras-CAAX : Selective inhibition of farnesyltransferase and Ras processing. Journal of Biological Chemistry 270, 660-664 (1995)
    36. McGuire, T.F., Qian, Y., Blaskovich, M.A., Fossum, R.D., Sun, J., Marlowe, T., Corey, S.J., Wathen, S.P., Vogt, A., Hamilton, A.D. and Sebti, S.M. Ras CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase. Biochemical and Biophysical Research Communications 214, 295-303 (1995)
    37. Qian, Y., Blaskovich, M.A., Seong, Ch.-M., Vogt, A., Hamilton, A.D., and Sebti, S.M., Peptidomimetic inhibitors of p21ras farnesyltransferase : Hydrophobic functionalization leads to disruption of p21 Ras membrane association in whole cells. Bioorganic and Medicinal Chemistry Letters 4, 2579-2584 (1994)
    38. Matthies, D., Siewers, S., und Vogt, A. , Reaktive Eigenschaften der C-Aryl-Glycin-Struktur; Synthese und Eigenschaften von Acylierungsprodukten des 3-Acylamino-5-methyl- 2(3H)-benzofuranons. Chemiker-Zeitung 114, 283-287 (1990).
       Health Sciences @ Pitt   |    UPMC   |    HSLS   |    School of Medicine   |    Health Sciences Calendar   |    Our News & Events  
    Top of Page  |  Home  |  Contact Us Last Update 6/28/2017
    © Office of the Senior Vice Chancellor for Health Sciences, University of Pittsburgh. All rights reserved.